Angela Holland-Ridges, DPM
Foot & Ankle Surgery · Brooklyn, NYNPI 1780941195
Payments from drug & device makers
Across 43 payments — averaging $125.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KCI USA, Inc.$2K
- Treace Medical Concepts, Inc.$1K
- Stryker$852
- Linvatec Corporation$538
- Paragon 28, Inc.$495
- Smith+Nephew$149
- plus $149 from 6 others
What the payments were for
- Travel & lodging$3,41063%
- Food & beverage$1,99437%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KCI USA, Inc. | 7 | $1,847 |
| Treace Medical Concepts, Inc. | 7 | $1,373 |
| Stryker | 10 | $852 |
| Linvatec Corporation | 1 | $538 |
| Paragon 28, Inc. | 4 | $495 |
| Smith+Nephew | 7 | $149 |
| AbbVie | 2 | $47 |
| Innovation Technologies Inc | 1 | $27 |
| Advanced Oxygen Therapy Inc. | 1 | $26 |
| AstraZeneca | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Globus Medical | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SNAP$1,825
- Lapiplasty System$1,218
- PREVENA$1,062
- BioBrace 23mm$538
- CITREFIX$318
- PROSTEP MICA$307
- EASYFUSE$307
- Portfolio$305
- ALLOWRAP$155
- PROstep$155
- AUGMENT INJECTABLE$155
- 7 X 23MM CITRELOCK IMPLANT$152
- Bun-Yo-Matic$150
- VAC ULTA$146
- VAC VERAFLO CLEANSE CHOICE$146
- ACTIVAC$146
How this compares
$5,404 in reported general payments places this provider in the 70th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxepin Hcl | 233 | $26,398 |
| Diclofenac Sodium ErDiclofenac Sodium | 207 | $16,413 |
| Fluocinonide | 88 | $6,924 |
| Clotrimazole | 81 | $3,331 |
| Fluconazole | 15 | $1,892 |
| Naproxen Sodium | 14 | $1,589 |
| Ketoconazole | 42 | $1,127 |
| Ammonium Lactate | 20 | $474 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $215 |
| Cephalexin | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Brooklyn
- Edward AzarBrooklyn$224K
- William SpielfogelBrooklyn$111K
- David MandilBrooklyn$56K
- Yury RotshteynBrooklyn$43K
- Mario VoloshinBrooklyn$33K
- Bryan MakowerBrooklyn$28K
- Amit GandhiBrooklyn$21K
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4.1M
- George Vitole Roy$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.